Morgan Stanley analyst Terence Flynn raised the firm’s price target on Structure Therapeutics (GPCR) to $125 from $120 and keeps an Overweight rating on the shares. The firm expects many of the policy overhangs that dominated the biopharma conversation this year to wane in 2026, bringing the focus back to fundamentals, the analyst tells investors in a 2026 outlook note for the group.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on GPCR:
- Structure Therapeutics price target raised to $120 from $87 at Citizens
- Structure Therapeutics price target raised to $125 from $79 at Jefferies
- Structure Therapeutics Announces $650 Million Public Offering
- Structure Therapeutics 8.5M share Spot Secondary priced at $65.00
- Structure Therapeutics Stock (GPCR) Spikes 102% as Obesity Trial Beats Eli Lilly, Novo Nordisk